The Role of the PAX Genes in Renal Cell Carcinoma
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25126730 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Lei Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9016, New Zealand. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Paired Box Transcription Factors. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 138 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chinese Scholarship Council–New Zealand-China Research Collaboration Centres, New Zealand-China Non-Communicable Diseases Research Collaboration Centre, New Zealand Institute for Cancer Research Trust.
Abstract (Originalsprache)
Renal cell carcinoma (RCC) is a significant oncological challenge due to its heterogeneous nature and limited treatment options. The PAX developmental gene family encodes nine highly conserved transcription factors that play crucial roles in embryonic development and organogenesis, which have been implicated in the occurrence and development of RCC. This review explores the molecular landscape of RCC, with a specific focus on the role of the PAX gene family in RCC tumorigenesis and disease progression. Of the various RCC subtypes, clear cell renal cell carcinoma (ccRCC) is the most prevalent, characterized by the loss of the von Hippel–Lindau (VHL) tumor suppressor gene. Here, we review the published literature on the expression patterns and functional implications of PAX genes, particularly PAX2 and PAX8, in the three most common RCC subtypes, including ccRCC, papillary RCC (PRCC), and chromophobe RCC (ChRCC). Further, we review the interactions and potential biological mechanisms involving PAX genes and VHL loss in driving the pathogenesis of RCC, including the key signaling pathways mediated by VHL in ccRCC and associated mechanisms implicating PAX. Lastly, concurrent with our update regarding PAX gene research in RCC, we review and comment on the targeting of PAX towards the development of novel RCC therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9016, New Zealand.
- Maurice Wilkins Centre for Molecular Biodiscovery, Level 2, 3A Symonds Street, Auckland 1010, New Zealand.
ORCID-Profile: Michael R Eccles
Förderung
- Chinese Scholarship Council–New Zealand-China Research Collaboration Centres
- New Zealand-China Non-Communicable Diseases Research Collaboration Centre
- New Zealand Institute for Cancer Research Trust
- Maurice Wilkins Centre for Molecular Biodiscovery
- Dunedin School of Medicine, University of Otago
Zitieren
APA
Li, L., Hossain, S. M., & Eccles, M. R. (2024). The Role of the PAX Genes in Renal Cell Carcinoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25126730
Vancouver
Li L, Hossain SM, Eccles MR. The Role of the PAX Genes in Renal Cell Carcinoma. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25126730
BibTeX
@article{Li2024,
author = {Li, Lei and Hossain, Sultana Mehbuba and Eccles, Michael R},
title = {The Role of the PAX Genes in Renal Cell Carcinoma},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25126730}
}
EUVIMED